Feb. 10 at 2:31 AM
$TRVI Here is the summary from a 2/5 Stifel research note: We sat with TRVI’s Jennifer Good (CEO) to discuss Haduvio’s well characterized profile in IPF-related chronic cough/IPF-CC and refractory chronic cough/RCC as well as the development path going forward in an evolving regulatory environment. Following key clinical readouts last year, TRVI is approaching its EOP2 meeting with FDA (1Q26) with aspirations to discuss a streamlined pivotal program in IPF-CC and identify a path for adding broader interstitial lung diseases/ILDs to the label. Separately, further exploration of Haduvio in RCC is ongoing with an aim to further investigate the dosing range and potentially create a separate brand for the indication. Though 2026 is a year of trial execution, TRVI is funded through 2028 with
$195MN in cash, covering each of its key clinical readouts in 2027 and commercial preparations.
